BR0009913A - Uso de um inibidor da sìntese de glicolipìdeos e um agente capaz de aumentar a taxa de degradação de glicolipìdeos, produto, e, composição farmacêutica - Google Patents
Uso de um inibidor da sìntese de glicolipìdeos e um agente capaz de aumentar a taxa de degradação de glicolipìdeos, produto, e, composição farmacêuticaInfo
- Publication number
- BR0009913A BR0009913A BR0009913-9A BR0009913A BR0009913A BR 0009913 A BR0009913 A BR 0009913A BR 0009913 A BR0009913 A BR 0009913A BR 0009913 A BR0009913 A BR 0009913A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- inhibitor
- glycolipids
- breakdown
- increasing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
"USO DE UM INIBIDOR DA SìNTESE DE GLICOLIPìDEOS E UM AGENTE CAPAZ DE AUMENTAR A TAXA DE DEGRADAçãO DE GLICOLIPìDEOS, PRODUTO, E, COMPOSIçãO FARMACêUTICA". A presente invenção provê o uso de um inibidor da síntese de glicolipideo, tal como N-butildeoxinojirimicina (NB-DNJ), N-butildeoxigalactonojirimicina (NN-DNJ) ou N-nonildeoxinojirirnicina (NN-DNJ), e um agente capaz de aumentar a taxa de degradação do glicolipídeo na fabricação de um medicamento para o tratamento de um distúrbio, que tenha pelo menos um componente com base no armazenamento de glicolipídeo. Tais distúrbios incluem a doença de Gaucher, a doença de Sandhoff, a doença de Fabry. A doença de Tay-Sachs, a doença de armazenamento C de Niemann-Pick, gangliosidose GMI, distúrbios genéticos em que o acúmulo de glicolipideo neuronal contribui para a patologia de doenças, por exemplo mucopolissacaridoses, distúrbios neurológicos em que o acúmulo de glicolipídeos neuronais contribui para a patologia da doença, por exemplo mucopolissacaridoses, distúrbios neurológicos em que o acúmulo de glicolipídeo contendo glicosilceramida contribui para a patologia de doenças tais como a doença de Alzheimer, o acidente vascular cerebral e a epílepsia, canceres de origem neuronal, tais como o glioblastoma e o astrocitoma, e canceres que se originem fora do tecido neuronal, mas apresentando-se com metástases neuronais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9909066.4A GB9909066D0 (en) | 1999-04-20 | 1999-04-20 | Therapies |
| PCT/GB2000/001560 WO2000062779A1 (en) | 1999-04-20 | 2000-04-20 | Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0009913A true BR0009913A (pt) | 2002-01-08 |
Family
ID=10851917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0009913-9A BR0009913A (pt) | 1999-04-20 | 2000-04-20 | Uso de um inibidor da sìntese de glicolipìdeos e um agente capaz de aumentar a taxa de degradação de glicolipìdeos, produto, e, composição farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20020142985A1 (pt) |
| EP (2) | EP1171128B1 (pt) |
| JP (1) | JP4633939B2 (pt) |
| AT (1) | ATE243037T1 (pt) |
| AU (1) | AU775842B2 (pt) |
| BR (1) | BR0009913A (pt) |
| CA (1) | CA2368812C (pt) |
| DE (1) | DE60003409T2 (pt) |
| ES (1) | ES2200865T3 (pt) |
| GB (1) | GB9909066D0 (pt) |
| IL (1) | IL140379A (pt) |
| MX (1) | MXPA01010707A (pt) |
| NO (1) | NO329035B1 (pt) |
| WO (1) | WO2000062779A1 (pt) |
| ZA (1) | ZA200108417B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| JP2003505430A (ja) * | 1999-07-26 | 2003-02-12 | ジー・ディー・サール・アンド・カンパニー | デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用 |
| GB0006539D0 (en) * | 2000-03-17 | 2000-05-10 | Oxford Glycosciences Uk Ltd | Therapies |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| AU2002241853A1 (en) * | 2001-01-12 | 2002-07-24 | Oxford Glycosciences (Uk) Ltd. | Mucopolysaccharidosis therapies |
| US20080185293A1 (en) * | 2002-03-27 | 2008-08-07 | Giselher Klose | Method and Apparatus for Decontamination of Fluid with One or More High Purity Electrodes |
| CN1780603A (zh) * | 2002-08-27 | 2006-05-31 | 雀巢制品公司 | 预防或治疗上皮组织损伤或毛发脱落 |
| US7429460B2 (en) | 2003-01-15 | 2008-09-30 | Yeda Research And Development Co., Ltd. | Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| US20090111812A1 (en) * | 2004-06-14 | 2009-04-30 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| EP1773401B1 (en) * | 2004-06-21 | 2013-01-02 | Medtronic, Inc. | Medical systems and methods for delivering compositions to cells |
| WO2006037069A1 (en) * | 2004-09-28 | 2006-04-06 | Allergan, Inc. | Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions |
| CN104758253A (zh) | 2006-01-24 | 2015-07-08 | 安迅生物制药公司 | 大分子微球的制备技术 |
| PT1986612E (pt) | 2006-02-07 | 2012-11-06 | Shire Human Genetic Therapies | Composição estável de glucocerebrosidase |
| CN105879047A (zh) | 2008-12-16 | 2016-08-24 | 建新公司 | 寡糖-蛋白缀合物 |
| WO2010111711A2 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Ganglioside biosynthesis modulators |
| AU2010281403B2 (en) | 2009-07-28 | 2016-03-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Gaucher disease |
| WO2012001641A1 (en) | 2010-06-30 | 2012-01-05 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical compositions |
| EP2863941B1 (en) | 2012-03-02 | 2018-12-19 | Shire Human Genetic Therapies, Inc. | Velaglucerase for treating type iii gaucher disease |
| US20150118221A1 (en) * | 2012-05-08 | 2015-04-30 | The John Hopkins University | Compositions and methods for treating cardiac hypertrophy |
| US20140099380A1 (en) | 2012-06-28 | 2014-04-10 | Ansun Biopharma, Inc. | Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| WO2014014938A1 (en) * | 2012-07-17 | 2014-01-23 | Amicus Therapeutics, Inc. | Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation |
| GB201407837D0 (en) * | 2014-05-02 | 2014-06-18 | Cambridge Entpr Ltd | Methods of cancer therapy |
| US9981021B1 (en) | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| WO2019132004A1 (ja) * | 2017-12-28 | 2019-07-04 | 国立大学法人熊本大学 | アルツハイマー病予防剤又は治療剤、そのスクリーニング方法、及びアルツハイマー病予防用又は治療用組成物 |
| NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
| WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
| JP2023512281A (ja) | 2020-02-03 | 2023-03-24 | ゲイン セラピューティクス エスアー | Ｍｐｓ１を処置するための併用療法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US182767A (en) * | 1876-10-03 | Improvement in window-screens | ||
| GB1555654A (en) | 1977-06-25 | 1979-11-14 | Exxon Research Engineering Co | Agricultural burner apparatus |
| DE2853573A1 (de) * | 1978-12-12 | 1980-07-03 | Bayer Ag | Herstellung von n-substituierten derivaten des l-desoxynojirimycins |
| DE3038901A1 (de) * | 1980-10-15 | 1982-05-06 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins |
| US5151519A (en) * | 1990-05-07 | 1992-09-29 | G. D. Searle & Co. | Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof |
| US6291657B1 (en) * | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
| IL128036A (en) * | 1996-07-15 | 2005-08-31 | Univ Amsterdam | Deoxynojirimycin derivatives comprising a polyclic alcohol group, pharmaceutical composition comprising a deoxynojirimycin derivative and uses thereof |
| US6610703B1 (en) * | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| GB9909064D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| JP2003505430A (ja) * | 1999-07-26 | 2003-02-12 | ジー・ディー・サール・アンド・カンパニー | デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用 |
| US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
-
1999
- 1999-04-20 GB GBGB9909066.4A patent/GB9909066D0/en not_active Ceased
-
2000
- 2000-04-20 BR BR0009913-9A patent/BR0009913A/pt not_active Application Discontinuation
- 2000-04-20 CA CA002368812A patent/CA2368812C/en not_active Expired - Lifetime
- 2000-04-20 JP JP2000611915A patent/JP4633939B2/ja not_active Expired - Fee Related
- 2000-04-20 EP EP00920920A patent/EP1171128B1/en not_active Expired - Lifetime
- 2000-04-20 AU AU41332/00A patent/AU775842B2/en not_active Ceased
- 2000-04-20 DE DE60003409T patent/DE60003409T2/de not_active Expired - Lifetime
- 2000-04-20 ES ES00920920T patent/ES2200865T3/es not_active Expired - Lifetime
- 2000-04-20 MX MXPA01010707A patent/MXPA01010707A/es active IP Right Grant
- 2000-04-20 EP EP03005215A patent/EP1321143A1/en not_active Withdrawn
- 2000-04-20 IL IL140379A patent/IL140379A/en not_active IP Right Cessation
- 2000-04-20 WO PCT/GB2000/001560 patent/WO2000062779A1/en active IP Right Grant
- 2000-04-20 AT AT00920920T patent/ATE243037T1/de not_active IP Right Cessation
-
2001
- 2001-10-12 ZA ZA200108417A patent/ZA200108417B/xx unknown
- 2001-10-19 US US10/042,527 patent/US20020142985A1/en not_active Abandoned
- 2001-10-19 NO NO20015111A patent/NO329035B1/no not_active IP Right Cessation
-
2004
- 2004-01-15 US US10/758,247 patent/US7348000B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050075305A1 (en) | 2005-04-07 |
| EP1171128A1 (en) | 2002-01-16 |
| AU775842B2 (en) | 2004-08-19 |
| ZA200108417B (en) | 2003-03-26 |
| DE60003409T2 (de) | 2004-05-19 |
| US7348000B2 (en) | 2008-03-25 |
| DE60003409D1 (de) | 2003-07-24 |
| IL140379A (en) | 2006-09-05 |
| IL140379A0 (en) | 2002-02-10 |
| ES2200865T3 (es) | 2004-03-16 |
| JP4633939B2 (ja) | 2011-02-16 |
| AU4133200A (en) | 2000-11-02 |
| WO2000062779A1 (en) | 2000-10-26 |
| NO20015111L (no) | 2001-12-12 |
| CA2368812A1 (en) | 2000-10-26 |
| EP1321143A1 (en) | 2003-06-25 |
| MXPA01010707A (es) | 2002-08-20 |
| US20020142985A1 (en) | 2002-10-03 |
| NO329035B1 (no) | 2010-08-02 |
| ATE243037T1 (de) | 2003-07-15 |
| NO20015111D0 (no) | 2001-10-19 |
| CA2368812C (en) | 2009-06-30 |
| JP2002542194A (ja) | 2002-12-10 |
| GB9909066D0 (en) | 1999-06-16 |
| EP1171128B1 (en) | 2003-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0009913A (pt) | Uso de um inibidor da sìntese de glicolipìdeos e um agente capaz de aumentar a taxa de degradação de glicolipìdeos, produto, e, composição farmacêutica | |
| NO20034612L (no) | 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer | |
| AR020662A1 (es) | Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento. | |
| EA200200183A1 (ru) | Композиция, содержащая трамадол и противосудорожное лекарственное средство | |
| ATE297204T1 (de) | Heilmittel für neurodegenerative krankheiten | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| MY127980A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
| KR960700742A (ko) | 아토피성질환 치료약(atopic disease remedy) | |
| BR9609019A (pt) | Compostos ativos em um novo local sobre canais de cálcio operados por receptor úteis no tratamento de desordens e doenças neurológicas | |
| SI2527315T1 (sl) | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen | |
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| IL179160A0 (en) | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | |
| WO2001053457A3 (en) | Vaccines against neurodegenerative disorders | |
| DK0915823T3 (da) | Biaromatiske forbindelser, farmaceutiske præparater og kosmetiske sammensætninger, der indeholder dem og anvendelser | |
| JP2005533051A5 (pt) | ||
| RU95106680A (ru) | Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции | |
| DK0832057T3 (da) | Diaromatiske propynyl- eller dienylforbindelser | |
| FI964482A0 (fi) | Amidijohdannaisia ja niiden käyttö lääkkeenä | |
| HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
| PL1631277T3 (pl) | Pochodne naturalnych, półsyntetycznych i syntetycznych lipidów z grupy ceramidów i sfingozyn, lek i jego zastosowanie jako środka leczniczego w medycynie, zwłaszcza w dermatologii | |
| DE60204046D1 (de) | N-heterocyclylhydrazide als neurotrophe mittel | |
| ZA200600165B (en) | Amino acid diamides in non alpha position useful as adjuvants for the administration of active biological agents | |
| FR2818147B1 (fr) | Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine | |
| GT200200002A (es) | Utilizacion de cromanos | |
| BRPI0408743A (pt) | formulações compreendendo tolterodina e cacau em pó e sua utilização |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ACTELION PHARMACEUTICALS LIMITED (CH) Free format text: TRANSFERIDO DE: OXFORD GLYCOSCIENCES (UK) LIMITED |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |